Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hematologic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT03485170
What this trial is testing

PET Imaging of Hemophilic Arthropathy

Who this might be right for
HemophiliaArthropathyInflammation
Tri-Service General Hospital (TSGH) 20
Testing effectiveness (Phase 2)Ended earlyNCT00017069
What this trial is testing

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
CTI BioPharma
Testing effectiveness (Phase 2)Study completedNCT02311569
What this trial is testing

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Who this might be right for
Myeloproliferative NeoplasmPrimary MyelofibrosisEssential Thrombocythemia+1 more
Swiss Cancer Institute 39
Testing effectiveness (Phase 2)Study completedNCT00812669
What this trial is testing

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Who this might be right for
Leukemia
Cancer Trials Ireland 52
Testing effectiveness (Phase 2)UnknownNCT01374841
What this trial is testing

Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors

Who this might be right for
Hematologic Neoplasms
European Institute of Oncology 20
Testing effectiveness (Phase 2)WithdrawnNCT01324960
What this trial is testing

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
Not applicableStudy completedNCT00069680
What this trial is testing

Genetic Analysis of Gray Platelet Syndrome

Who this might be right for
Genetic LinkageMyelofibrosis
National Human Genome Research Institute (NHGRI) 123
Not applicableStudy completedNCT02584296
What this trial is testing

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

Who this might be right for
LeukemiaMyeloidMonocytic
Virginia Commonwealth University 23
Testing effectiveness (Phase 2)Looking for participantsNCT03128996
What this trial is testing

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Who this might be right for
Severe Sickle Cell DiseaseBone Marrow Failure SyndromesMetabolic Disorders+3 more
Washington University School of Medicine 29
Early research (Phase 1)Study completedNCT02561962
What this trial is testing

Study in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 42
Large-scale testing (Phase 3)Study completedNCT02292446
What this trial is testing

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Who this might be right for
Polycythemia Vera
Novartis Pharmaceuticals 161
Early research (Phase 1)Not Yet RecruitingNCT07091370
What this trial is testing

Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy

Who this might be right for
AIHA - Cold Autoimmune Hemolytic Anemia
Juventas Cell Therapy Ltd. 12
Testing effectiveness (Phase 2)Looking for participantsNCT04322383
What this trial is testing

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Who this might be right for
Hairy Cell Leukemia
National Cancer Institute (NCI) 40
Not applicableUnknownNCT02045654
What this trial is testing

Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Samsung Medical Center 1
Not applicableUnknownNCT00192829
What this trial is testing

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell Lung CarcinomaVenous Thromboembolism
Rambam Health Care Campus 100
Not applicableStudy completedNCT06134102
What this trial is testing

Clinical and Laboratory Characteristics of Polycythemia Vera

Who this might be right for
Polycythemia Vera
IRCCS Azienda Ospedaliero-Universitaria di Bologna 1,150
Large-scale testing (Phase 3)Study completedNCT02997202
What this trial is testing

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 356
Not applicableStudy completedNCT01437202
What this trial is testing

Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia

Who this might be right for
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asan Medical Center 100
Post-approval studies (Phase 4)UnknownNCT02013102
What this trial is testing

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Cttq 240
Testing effectiveness (Phase 2)Ended earlyNCT04240002
What this trial is testing

Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Astellas Pharma Global Development, Inc. 9
Next Page